Researcher from Royal Free London NHS Foundation Trust Reports Details of New Studies and Findings in the Area of CD20 Monoclonal Antibodies (E005 Immunoglobulins review prior to rituximab infusion: implications and how we can improve our...).
In: Immunotherapy Weekly, 2024-05-14, S. 2199-2199
serialPeriodical
Zugriff:
A recent report from the Royal Free London NHS Foundation Trust discusses the importance of monitoring immunoglobulin levels in patients receiving rituximab (RTX) infusions, a treatment for autoimmune and lymphoproliferative diseases. The study found that there was a lack of protocolized approach to measuring immunoglobulin levels prior to or between RTX infusions, leading to treatment cancellations and potential harm to patients. The researchers implemented measures to improve monitoring standards, including reviewing pre-screening tests, updating pharmacy checklists, and taking urgent blood samples if necessary. The next steps will involve measuring the impact of these changes on patient safety and treatment cancellations. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researcher from Royal Free London NHS Foundation Trust Reports Details of New Studies and Findings in the Area of CD20 Monoclonal Antibodies (E005 Immunoglobulins review prior to rituximab infusion: implications and how we can improve our...).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-05-14, S. 2199-2199 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|